RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

REGENXBIO shares fell 25% after the FDA placed a clinical hold on RGX-121 for MPS II. The hold follows asymptomatic spine MRI findings in five participants, delaying the program’s clinical progress. The news is a material negative catalyst given the direct regulatory impact on the lead asset.